Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study is a research paper published in Journal of Clinical Oncology (2022). On theSindex it has a DataRank of 2.9. It has been cited 99 times, with 84 citing works in its 1-hop citation network.
Scored on demand from live citation data
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.691
From this paper's citation signal
Citation Network Contribution
2.2
From 63 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 84 citers.